Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00470366 · ClinicalTrials.gov registry record · Phase 2

Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors

A Phase 2 study of Ovarian Cancer and Brain and Central Nervous System Tumors, sponsored by Memorial Sloan Kettering Cancer Center.

Completed
Registry status
Phase 2
Development phase
60
Enrollment target
2
Study locations

NCT00470366 is a Phase 2 study of Ovarian Cancer and Brain and Central Nervous System Tumors that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 60 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (92% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00470366, a Phase 2 study of Ovarian Cancer and Brain and Central Nervous System Tumors, has completed, sponsored by Memorial Sloan Kettering Cancer Center.

COMPLETED
Registry status
Phase 2
Development phase
60 participants
Enrollment target
2
Study locations

Study Summary

RATIONALE: Drugs used in chemotherapy, such as cisplatin, ifosfamide, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Colony-stimulating factors, such as pegfilgrastim, may increase the number of immune cells found in bone marrow or peripheral blood and may help the immune system recover from the side effects of chemotherapy. PURPOSE: This phase II trial is studying the side effects and how well giving combination chemotherapy together with pegfilgrastim works in treating patients with previously untreated germ cell tumors.

Conditions Studied

Ovarian Cancer Brain and Central Nervous System Tumors Testicular Germ Cell Tumor Teratoma Extragonadal Germ Cell Tumor

Interventions

  • DRUG cisplatin
  • DRUG paclitaxel
  • DRUG ifosfamide
  • BIOLOGICAL pegfilgrastim

Study Locations (2)

California

  • USC/Norris Comprehensive Cancer Center and Hospital - Los Angeles

New York

  • Memorial Sloan-Kettering Cancer Center - New York

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2007-03
Est. Completion 2016-06
Phase Phase 2

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00470366

The ClinicalTrials.gov registry entry for NCT00470366 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (92% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 4 interventions - of which cisplatin is the first listed.

NCT00470366 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, New York.

Frequently Asked Questions

What is clinical trial NCT00470366 about?

NCT00470366 is a clinical study titled "Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors". RATIONALE: Drugs used in chemotherapy, such as cisplatin, ifosfamide, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Colony-stimul...

What is the current status of trial NCT00470366?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2007-03. Estimated completion is 2016-06.

What conditions does trial NCT00470366 study?

This clinical trial studies the following conditions: Ovarian Cancer, Brain and Central Nervous System Tumors, Testicular Germ Cell Tumor, Teratoma, Extragonadal Germ Cell Tumor.

What interventions are being tested in trial NCT00470366?

The interventions under investigation include: cisplatin (DRUG), paclitaxel (DRUG), ifosfamide (DRUG), pegfilgrastim (BIOLOGICAL).

Who is sponsoring clinical trial NCT00470366?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00470366 being conducted?

This trial has 2 study locations across California, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Ovarian Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Ovarian Cancer

All registered trials for this condition

Brain and Central Nervous System Tumors

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.